Mitochondria as Therapeutic Target for Acute Brain Pathologies

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Molecular and Cellular Neuroscience".

Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 34738

Special Issue Editors


E-Mail Website1 Website2
Guest Editor
Department of Functional Biochemistry of Biopolymers, A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia
Interests: mitochondria; reactive oxygen species; oxidative stress; aging; ischemia; inflammation
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Laboratory of the Structure and Function of Mitochondria, A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia
2. Lab Stem Cells Technology, V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, 117997 Moscow, Russia
Interests: cerebral ischemia; stroke, trauma; mitochondrial traffic; neuroprotection; ischemic preconditioning; autophagy; aging; intercellular communication
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Different etiological factors that cause occlusion of blood supply or gas exchange in the brain can lead to the development of acute pathological conditions of the brain, such as ischemic stroke or encephalopathy of newborns. Brain ischemia can also be secondary to traumatic brain injury, brain tumor compression, or surgical treatment. Mitochondria not only play a central role in many signalling pathways associated with numerous pathologies; they are involved in the mechanism of neuroprotection accompanied with reactive oxygen species (ROS) signalling pathways, thus making this organelle the main target of any anti-ischemic protective or post-injury therapeutic strategy. Therefore, modulating mitochondrial function has emerged as an attractive therapeutic strategy for a range of brain pathologies to promote development of drugs based on fundamental discoveries in this area.

The present Special Issue aims to gather original research studies as well as perspectives and reviews that provide future directions for and advances in the use of mitochondria as the target for therapeutic approaches in treatment of several diseases, which includes pharmacological drugs acting via the regulation of: calcium and redox homeostasis, permeability transition pores, mitochondrial dynamics and biogenesis, mitophagy, mitochondrial preconditioning, intercellular transport of mitochondria, and mitochondrial transplantation.

Prof. Dr. Dmitry Zorov
Dr. Denis Silachev
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Brain
  • Stroke
  • Traumatic brain injury
  • Mitochondria
  • Neuroprotection
  • Pathophysiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (10 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

30 pages, 5326 KiB  
Article
Protective Effects of PGC-1α Activators on Ischemic Stroke in a Rat Model of Photochemically Induced Thrombosis
by Fatima M. Shakova, Yuliya I. Kirova, Denis N. Silachev, Galina A. Romanova and Sergey G. Morozov
Brain Sci. 2021, 11(3), 325; https://doi.org/10.3390/brainsci11030325 - 4 Mar 2021
Cited by 4 | Viewed by 3872
Abstract
The pharmacological induction and activation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α), a key regulator of ischemic brain tolerance, is a promising direction in neuroprotective therapy. Pharmacological agents with known abilities to modulate cerebral PGC-1α are scarce. This study focused on [...] Read more.
The pharmacological induction and activation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α), a key regulator of ischemic brain tolerance, is a promising direction in neuroprotective therapy. Pharmacological agents with known abilities to modulate cerebral PGC-1α are scarce. This study focused on the potential PGC-1α-modulating activity of Mexidol (2-ethyl-6-methyl-3-hydroxypyridine succinate) and Semax (ACTH(4–7) analog) in a rat model of photochemical-induced thrombosis (PT) in the prefrontal cortex. Mexidol (100 mg/kg) was administered intraperitoneally, and Semax (25 μg/kg) was administered intranasally, for 7 days each. The expression of PGC-1α and PGC-1α-dependent protein markers of mitochondriogenesis, angiogenesis, and synaptogenesis was measured in the penumbra via immunoblotting at Days 1, 3, 7, and 21 after PT. The nuclear content of PGC-1α was measured immunohistochemically. The suppression of PGC-1α expression was observed in the penumbra from 24 h to 21 days following PT and reflected decreases in both the number of neurons and PGC-1α expression in individual neurons. Administration of Mexidol or Semax was associated with preservation of the neuron number and neuronal expression of PGC-1α, stimulation of the nuclear translocation of PGC-1α, and increased contents of protein markers for PGC-1α activation. This study opens new prospects for the pharmacological modulation of PGC-1α in the ischemic brain. Full article
(This article belongs to the Special Issue Mitochondria as Therapeutic Target for Acute Brain Pathologies)
Show Figures

Figure 1

21 pages, 2714 KiB  
Article
Potential Effects of Poloxamer 188 on Rat Isolated Brain Mitochondria after Oxidative Stress In Vivo and In Vitro
by Johannes A. Pille and Matthias L. Riess
Brain Sci. 2021, 11(1), 122; https://doi.org/10.3390/brainsci11010122 - 18 Jan 2021
Cited by 8 | Viewed by 2786
Abstract
Outcome after cerebral ischemia is often dismal. Reperfusion adds significantly to the ischemic injury itself. Therefore, new strategies targeting ischemia/reperfusion (I/R) injury are critically needed. Poloxamer (P)188, an amphiphilic triblock copolymer, is a highly promising pharmacological therapeutic as its capability to insert into [...] Read more.
Outcome after cerebral ischemia is often dismal. Reperfusion adds significantly to the ischemic injury itself. Therefore, new strategies targeting ischemia/reperfusion (I/R) injury are critically needed. Poloxamer (P)188, an amphiphilic triblock copolymer, is a highly promising pharmacological therapeutic as its capability to insert into injured cell membranes has been reported to protect against I/R injury in various models. Although mitochondrial function particularly profits from P188 treatment after I/R, it remains unclear if this beneficial effect occurs directly or indirectly. Here, rat isolated brain mitochondria underwent oxidative stress in vivo by asphyxial cardiac arrest or in vitro by the addition of hydrogen peroxide (H2O2) after isolation. Mitochondrial function was assessed by adenosine triphosphate synthesis, oxygen consumption, and calcium retention capacity. Both asphyxia and H2O2 exposure significantly impaired mitochondrial function. P188 did not preserve mitochondrial function after either injury mechanism. Further research is indicated. Full article
(This article belongs to the Special Issue Mitochondria as Therapeutic Target for Acute Brain Pathologies)
Show Figures

Figure 1

18 pages, 4085 KiB  
Article
Loss of the Mitochondrial Fission GTPase Drp1 Contributes to Neurodegeneration in a Drosophila Model of Hereditary Spastic Paraplegia
by Philippa C. Fowler, Dwayne J. Byrne, Craig Blackstone and Niamh C. O'Sullivan
Brain Sci. 2020, 10(9), 646; https://doi.org/10.3390/brainsci10090646 - 17 Sep 2020
Cited by 11 | Viewed by 4642
Abstract
Mitochondrial morphology, distribution and function are maintained by the opposing forces of mitochondrial fission and fusion, the perturbation of which gives rise to several neurodegenerative disorders. The large guanosine triphosphate (GTP)ase dynamin-related protein 1 (Drp1) is a critical regulator of mitochondrial fission by [...] Read more.
Mitochondrial morphology, distribution and function are maintained by the opposing forces of mitochondrial fission and fusion, the perturbation of which gives rise to several neurodegenerative disorders. The large guanosine triphosphate (GTP)ase dynamin-related protein 1 (Drp1) is a critical regulator of mitochondrial fission by mediating membrane scission, often at points of mitochondrial constriction at endoplasmic reticulum (ER)-mitochondrial contacts. Hereditary spastic paraplegia (HSP) subtype SPG61 is a rare neurodegenerative disorder caused by mutations in the ER-shaping protein Arl6IP1. We have previously reported defects in both the ER and mitochondrial networks in a Drosophila model of SPG61. In this study, we report that knockdown of Arl6IP1 lowers Drp1 protein levels, resulting in reduced ER–mitochondrial contacts and impaired mitochondrial load at the distal ends of long motor neurons. Increasing mitochondrial fission, by overexpression of wild-type Drp1 but not a dominant negative Drp1, increases ER–mitochondrial contacts, restores mitochondrial load within axons and partially rescues locomotor deficits. Arl6IP1 knockdown Drosophila also demonstrate impaired autophagic flux and an accumulation of ubiquitinated proteins, which occur independent of Drp1-mediated mitochondrial fission defects. Together, these findings provide evidence that impaired mitochondrial fission contributes to neurodegeneration in this in vivo model of HSP. Full article
(This article belongs to the Special Issue Mitochondria as Therapeutic Target for Acute Brain Pathologies)
Show Figures

Figure 1

12 pages, 2736 KiB  
Article
Neuroanatomical Changes in Leber’s Hereditary Optic Neuropathy: Clinical Application of 7T MRI Submillimeter Morphometry
by Kamil Jonak, Paweł Krukow, Mark Symms, Ryszard Maciejewski and Cezary Grochowski
Brain Sci. 2020, 10(6), 359; https://doi.org/10.3390/brainsci10060359 - 9 Jun 2020
Cited by 10 | Viewed by 3820
Abstract
Leber’s hereditary optic neuropathy (LHON) is one of the mitochondrial diseases that causes loss of central vision, progressive impairment and subsequent degeneration of retinal ganglion cells (RGCs). In recent years, diffusion tensor imaging (DTI) studies have revealed structural abnormalities in visual white matter [...] Read more.
Leber’s hereditary optic neuropathy (LHON) is one of the mitochondrial diseases that causes loss of central vision, progressive impairment and subsequent degeneration of retinal ganglion cells (RGCs). In recent years, diffusion tensor imaging (DTI) studies have revealed structural abnormalities in visual white matter tracts, such as the optic tract, and optic radiation. However, it is still unclear if the disease alters only some parts of the white matter architecture or whether the changes also affect other subcortical areas of the brain. This study aimed to improve our understanding of morphometric changes in subcortical brain areas and their associations with the clinical picture in LHON by the application of a submillimeter surface-based analysis approach to the ultra-high-field 7T magnetic resonance imaging data. To meet these goals, fifteen LHON patients and fifteen age-matched healthy subjects were examined. For all individuals, quantitative analysis of the morphometric results was performed. Furthermore, morphometric characteristics which differentiated the groups were correlated with variables covering selected aspects of the LHON clinical picture. Compared to healthy controls (HC), LHON carriers showed significantly lower volume of both palladiums (left p = 0.023; right p = 0.018), the right accumbens area (p = 0.007) and the optic chiasm (p = 0.014). Additionally, LHON patients have significantly higher volume of both lateral ventricles (left p = 0.034; right p = 0.02), both temporal horns of the lateral ventricles (left p = 0.016; right p = 0.034), 3rd ventricle (p = 0.012) and 4th ventricle (p = 0.002). Correlation between volumetric results and clinical data showed that volume of both right and left lateral ventricles significantly and positively correlated with the duration of the illness (left R = 0.841, p = 0.002; right R = 0.755, p = 0.001) and the age of the LHON participants (left R = 0.656, p = 0.007; right R = 0.691, p = 0.004). The abnormalities in volume of the LHON patients’ subcortical structures indicate that the disease can cause changes not only in the white matter areas constituting visual tracts, but also in the other subcortical brain structures. Furthermore, the correlation between those results and the illness duration suggests that the disease might have a neurodegenerative nature; however, to fully confirm this observation, longitudinal studies should be conducted. Full article
(This article belongs to the Special Issue Mitochondria as Therapeutic Target for Acute Brain Pathologies)
Show Figures

Figure 1

Review

Jump to: Research, Other

15 pages, 860 KiB  
Review
Neuroprotective Potential of Mild Uncoupling in Mitochondria. Pros and Cons
by Dmitry B. Zorov, Nadezda V. Andrianova, Valentina A. Babenko, Irina B. Pevzner, Vasily A. Popkov, Savva D. Zorov, Ljubava D. Zorova, Egor Yu. Plotnikov, Gennady T. Sukhikh and Denis N. Silachev
Brain Sci. 2021, 11(8), 1050; https://doi.org/10.3390/brainsci11081050 - 8 Aug 2021
Cited by 17 | Viewed by 3764
Abstract
There has been an explosion of interest in the use of uncouplers of oxidative phosphorylation in mitochondria in the treatment of several pathologies, including neurological ones. In this review, we analyzed all the mechanisms associated with mitochondrial uncoupling and the metabolic and signaling [...] Read more.
There has been an explosion of interest in the use of uncouplers of oxidative phosphorylation in mitochondria in the treatment of several pathologies, including neurological ones. In this review, we analyzed all the mechanisms associated with mitochondrial uncoupling and the metabolic and signaling cascades triggered by uncouplers. We provide a full set of positive and negative effects that should be taken into account when using uncouplers in experiments and clinical practice. Full article
(This article belongs to the Special Issue Mitochondria as Therapeutic Target for Acute Brain Pathologies)
Show Figures

Figure 1

14 pages, 798 KiB  
Review
p62-Nrf2-p62 Mitophagy Regulatory Loop as a Target for Preventive Therapy of Neurodegenerative Diseases
by Artem P. Gureev, Irina S. Sadovnikova, Natalia N. Starkov, Anatoly A. Starkov and Vasily N. Popov
Brain Sci. 2020, 10(11), 847; https://doi.org/10.3390/brainsci10110847 - 12 Nov 2020
Cited by 39 | Viewed by 4125
Abstract
Turnover of the mitochondrial pool due to coordinated processes of mitochondrial biogenesis and mitophagy is an important process in maintaining mitochondrial stability. An important role in this process is played by the Nrf2/ARE signaling pathway, which is involved in the regulation of the [...] Read more.
Turnover of the mitochondrial pool due to coordinated processes of mitochondrial biogenesis and mitophagy is an important process in maintaining mitochondrial stability. An important role in this process is played by the Nrf2/ARE signaling pathway, which is involved in the regulation of the expression of genes responsible for oxidative stress protection, regulation of mitochondrial biogenesis, and mitophagy. The p62 protein is a multifunctional cytoplasmic protein that functions as a selective mitophagy receptor for the degradation of ubiquitinated substrates. There is evidence that p62 can positively regulate Nrf2 by binding to its negative regulator, Keap1. However, there is also strong evidence that Nrf2 up-regulates p62 expression. Thereby, a regulatory loop is formed between two important signaling pathways, which may be an important target for drugs aimed at treating neurodegeneration. Constitutive activation of p62 in parallel with Nrf2 would most likely result in the activation of mTORC1-mediated signaling pathways that are associated with the development of malignant neoplasms. The purpose of this review is to describe the p62-Nrf2-p62 regulatory loop and to evaluate its role in the regulation of mitophagy under various physiological conditions. Full article
(This article belongs to the Special Issue Mitochondria as Therapeutic Target for Acute Brain Pathologies)
Show Figures

Figure 1

13 pages, 710 KiB  
Review
Role of NAD+—Modulated Mitochondrial Free Radical Generation in Mechanisms of Acute Brain Injury
by Nina Klimova, Adam Fearnow and Tibor Kristian
Brain Sci. 2020, 10(7), 449; https://doi.org/10.3390/brainsci10070449 - 14 Jul 2020
Cited by 11 | Viewed by 4052
Abstract
It is commonly accepted that mitochondria represent a major source of free radicals following acute brain injury or during the progression of neurodegenerative diseases. The levels of reactive oxygen species (ROS) in cells are determined by two opposing mechanisms—the one that produces free [...] Read more.
It is commonly accepted that mitochondria represent a major source of free radicals following acute brain injury or during the progression of neurodegenerative diseases. The levels of reactive oxygen species (ROS) in cells are determined by two opposing mechanisms—the one that produces free radicals and the cellular antioxidant system that eliminates ROS. Thus, the balance between the rate of ROS production and the efficiency of the cellular detoxification process determines the levels of harmful reactive oxygen species. Consequently, increase in free radical levels can be a result of higher rates of ROS production or due to the inhibition of the enzymes that participate in the antioxidant mechanisms. The enzymes’ activity can be modulated by post-translational modifications that are commonly altered under pathologic conditions. In this review we will discuss the mechanisms of mitochondrial free radical production following ischemic insult, mechanisms that protect mitochondria against free radical damage, and the impact of post-ischemic nicotinamide adenine mononucleotide (NAD+) catabolism on mitochondrial protein acetylation that affects ROS generation and mitochondrial dynamics. We propose a mechanism of mitochondrial free radical generation due to a compromised mitochondrial antioxidant system caused by intra-mitochondrial NAD+ depletion. Finally, the interplay between different mechanisms of mitochondrial ROS generation and potential therapeutic approaches are reviewed. Full article
(This article belongs to the Special Issue Mitochondria as Therapeutic Target for Acute Brain Pathologies)
Show Figures

Figure 1

Other

Jump to: Research, Review

9 pages, 2021 KiB  
Brief Report
Effect of Xenon Treatment on Gene Expression in Brain Tissue after Traumatic Brain Injury in Rats
by Anton D. Filev, Denis N. Silachev, Ivan A. Ryzhkov, Konstantin N. Lapin, Anastasiya S. Babkina, Oleg A. Grebenchikov and Vladimir M. Pisarev
Brain Sci. 2021, 11(7), 889; https://doi.org/10.3390/brainsci11070889 - 3 Jul 2021
Cited by 11 | Viewed by 2941
Abstract
The overactivation of inflammatory pathways and/or a deficiency of neuroplasticity may result in the delayed recovery of neural function in traumatic brain injury (TBI). A promising approach to protecting the brain tissue in TBI is xenon (Xe) treatment. However, xenon’s mechanisms of action [...] Read more.
The overactivation of inflammatory pathways and/or a deficiency of neuroplasticity may result in the delayed recovery of neural function in traumatic brain injury (TBI). A promising approach to protecting the brain tissue in TBI is xenon (Xe) treatment. However, xenon’s mechanisms of action remain poorly clarified. In this study, the early-onset expression of 91 target genes was investigated in the damaged and in the contralateral brain areas (sensorimotor cortex region) 6 and 24 h after injury in a TBI rat model. The expression of genes involved in inflammation, oxidation, antioxidation, neurogenesis and neuroplasticity, apoptosis, DNA repair, autophagy, and mitophagy was assessed. The animals inhaled a gas mixture containing xenon and oxygen (ϕXe = 70%; ϕO2 25–30% 60 min) 15–30 min after TBI. The data showed that, in the contralateral area, xenon treatment induced the expression of stress genes (Irf1, Hmox1, S100A8, and S100A9). In the damaged area, a trend towards lower expression of the inflammatory gene Irf1 was observed. Thus, our results suggest that xenon exerts a mild stressor effect in healthy brain tissue and has a tendency to decrease the inflammation following damage, which might contribute to reducing the damage and activating the early compensatory processes in the brain post-TBI. Full article
(This article belongs to the Special Issue Mitochondria as Therapeutic Target for Acute Brain Pathologies)
Show Figures

Figure 1

2 pages, 147 KiB  
Reply
Reply: Factors Influencing Central Nervous System Abnormalities in m.11778G>A Carriers
by Cezary Grochowski and Kamil Jonak
Brain Sci. 2020, 10(8), 518; https://doi.org/10.3390/brainsci10080518 - 5 Aug 2020
Viewed by 1551
Abstract
First of all, I would like to thank the reader for their interest and taking the time to analyze our work [...] Full article
(This article belongs to the Special Issue Mitochondria as Therapeutic Target for Acute Brain Pathologies)
2 pages, 171 KiB  
Letter
Factors Influencing Central Nervous System Abnormalities in m.11778G>A Carriers
by Josef Finsterer
Brain Sci. 2020, 10(8), 513; https://doi.org/10.3390/brainsci10080513 - 3 Aug 2020
Cited by 1 | Viewed by 1871
Abstract
With interest, we read the article by Jonak et al [...] Full article
(This article belongs to the Special Issue Mitochondria as Therapeutic Target for Acute Brain Pathologies)
Back to TopTop